#5730 PERLECAN AS A POTENTIAL BIOMARKER OF CARDIOVASCULAR RISK: ROLE OF ENDOTHELIAL GLYCOCALYX IN CHRONIC KIDNEY DISEASE

Abstract Background and Aims Chronic kidney disease (CKD) is associated with cardiovascular (CVD). CVD in turn related to endothelial dysfunction, degradation of the glycocalyx (EG), releasing its components into bloodstream. The EG consists glycosaminoglycans proteoglycans, such as Perlecan. aim study analyse levels perlecan plasma different stages CKD, relate them age inflammatory monocytes, well their adhesion capacity (CD54/ICAM-1). Method An observational cross-sectional was carried out. 56 patients were included: advanced chronic (ACKD) (n=13), haemodialysis (HD) peritoneal dialysis (PD) (n=15) transplant recipients (TX) (n=15). Thirteen healthy subjects (CT) analysed. Plasma quantified using ELISA phenotyping monocyte subpopulations (classical (CD14++CD16-), intermediate (CD14+CD16+) non-classical (CD14+CD16++)), CD54 (ICAM-1) expression by flow cytometry. Statistical analysis: ANOVA Spearman correlation. Results Patients CKD had higher than participants (p-value = 0.044 vs ACKD, 0.028 HD 0.002 PD) (Fig. 1). These percentage classical monocytes (p=0,011) (p=0,009) (p=0,003) expressing ICAM-1 but not a per monocyte. Perlecan correlate negatively (p=0,03) (Table Conclusion PD have elevated compared CT TX. Elevated concentrations are increased on which important for possible role development atherosclerosis. may be postulated molecule interest assess damage patients.